Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment

Table 1 Baseline demographics of participants with mental health disease treated with ledipasvir-sofosbuvir n (%)

	SPARE (n = 23)	SYNERGY A (n = 7)	ERADICATE (n = 15)	P value
Demographic
Age, mean ± SD	54 ± 6	52 ± 10	56 ± 8	0.44
Male gender	14 (61)	5 (71)	9 (60)	0.86
Race or ethnicity				0.68
White	4 (17)	2 (29)	2 (13)	-
Black	19 (83)	5 (71)	13 (87)	-
Hispanic	0	0	0	-
HCV genotype 1 subtype				0.46
1A	18 (78)	4 (57)	12 (80)	-
1B	5 (22)	3 (43)	3 (20)	-
HIV +	0 (0)	0 (0)	15 (100)	< 0.0001
Mental health disorder
Depression	14 (61)	4 (57)	8 (53)	0.89
Anxiety	4 (17)	3 (43)	1 (7)	0.12
Bipolar disorder	4 (17)	3 (43)	5 (33)	0.32
Post-traumatic stress disorder	2 (7)	1 (14)	3 (20)	0.60
Schizophrenia	0	1 (14)	0	-

HCV: Hepatitis C virus; HIV: Human immunodeficiency virus.

Table 2 Baseline demographics of participants with hepatitis C/human immunodeficiency virus coinfection who had baseline, during, and post-treatment Beck’s Depression Inventory scoring analyzed n (%)

Demographic	Sofosbuvir-based therapy (n = 50)	Interferon-based therapy (n = 26)	P value
Age, median	58	47
Male	37 (74)	22 (84)	0.79
African American	42 (84)	11 (42)	0.0004
Fibrosis			0.00132
F0-1	35 (70)	10 (38)
F2-4	15 (30)	16 (62)
SVR	49 (98)	13 (50)	0.0001
Baseline mental health disease	15 (30)	15 (58)	0.0264

SVR: Sustained virologic response.